Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Abivax (ABVX) EBIT Margin: 2022-2025

Historic EBIT Margin for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to 723.22%.

  • Abivax's EBIT Margin rose 11467806.00% to 723.22% in Q2 2025 from the same period last year, while for Jun 2025 it was 1,077.06%, marking a year-over-year decrease of 67821.00%. This contributed to the annual value of -1,389.54% for FY2024, which is 136692.00% up from last year.
  • According to the latest figures from Q2 2025, Abivax's EBIT Margin is 723.22%, which was down 28.49% from 1,011.36% recorded in Q1 2025.
  • Abivax's EBIT Margin's 5-year high stood at 1,011.36% during Q1 2025, with a 5-year trough of -113,954.84% in Q2 2024.
  • Moreover, its 3-year median value for EBIT Margin was 361.82% (2023), whereas its average is -18,539.35%.
  • In the last 5 years, Abivax's EBIT Margin slumped by 40bps in 2024 and then surged by 11,467,806bps in 2025.
  • Over the past 4 years, Abivax's EBIT Margin (Quarterly) stood at -1,408.70% in 2022, then spiked by 140,912bps to 0.42% in 2023, then tumbled by 40bps to 0.02% in 2024, then soared by 11,467,806bps to 723.22% in 2025.
  • Its EBIT Margin was 723.22% in Q2 2025, compared to 1,011.36% in Q1 2025 and 0.02% in Q4 2024.